Comparative Pharmacology
Head-to-head clinical analysis: AMIKACIN SULFATE versus NEBCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMIKACIN SULFATE versus NEBCIN.
AMIKACIN SULFATE vs NEBCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting protein synthesis. Also disrupts bacterial cell membrane integrity.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting bacterial protein synthesis.
15 mg/kg/day IV or IM divided every 8-12 hours; typical adult dose 500 mg IV/IM every 12 hours or 7.5 mg/kg every 12 hours.
3-6 mg/kg/day IV in 2-3 divided doses every 8-12 hours; adjust based on serum levels and renal function.
None Documented
None Documented
Terminal: 2-3 hours (normal renal function); prolonged to 30-50 hours in anuria; neonates 4-8 hours.
Terminal elimination half-life is 2-3 hours in patients with normal renal function. Prolonged to 24-48 hours in anuria. Clinical context: Dosing interval adjustment required in renal impairment to avoid toxicity.
Renal: >90% unchanged via glomerular filtration. Biliary/fecal: <1%.
Renal excretion of unchanged drug accounts for >90% of elimination. Approximately 10% is excreted in bile.
Category D/X
Category C
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic